(1434–1466) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

Monday, October 27, 2025

10:30 AM - 12:30 PM Central Time

Location: Hall F1

CE: 0.00

Presentations:

10:30 AM - 12:30 PM Central Time

Angiogenesis Markers in Difficult to Treat Psoriatic Arthritis Patients
Abstract Poster Presenter: Devy Zisman, MD – Carmel Medical Center
10:30 AM - 12:30 PM Central Time

Bimekizumab Demonstrated Comparable One-Year Efficacy in Male and Female Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Abstract Poster Presenter: Lianne S. Gensler, MD – University of California San Francisco
10:30 AM - 12:30 PM Central Time

Bimekizumab in Psoriatic Arthritis. A real-world prospective study. Comparison of its efficacy in bDMARD-naive and IL-17A-experienced patients
Abstract Poster Presenter: George Fragoulis, MD, PhD (he/him/his) – "Laiko" Hospital - First Department of Propaedeutic and Internal Medicine
10:30 AM - 12:30 PM Central Time

Bimekizumab was Efficacious Regardless of Age, BMI, CRP, or HLA-B27 Status: 1-Year Results from Two Phase 3 Studies
Abstract Poster Presenter: Marina Magrey, MD – Case Western Reserve University School of Medicine/University Hospitals Cleveland
10:30 AM - 12:30 PM Central Time

Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Other Indications
Abstract Poster Presenter: Eugenia Levi, PharmD – Oruka
10:30 AM - 12:30 PM Central Time

Clinical and Demographic Characteristics of Treatment-Refractory Axial Spondyloarthritis: Data from the Greek AxSpA Registry
Abstract Poster Presenter: Nikolaos Kougkas, MD;PhD (he/him/his) – 4th Department of Internal Medicine, Aristotle University
10:30 AM - 12:30 PM Central Time

Clinical Efficacy of Bimekizumab Treatment up to 2 Years Across Patients with Psoriatic Arthritis and Varying Baseline Joint Involvement: Results from a Post Hoc Analysis of Two Pooled Phase 3 Studies
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
10:30 AM - 12:30 PM Central Time

Comparison of standard and tapered dose of biologic treatments in patients with axial spondyloarthritis
Abstract Poster Presenter: gEZMIS KIMYON, ASS.PROF MD – MUSTAFA KEMAL UNIVERSITY
10:30 AM - 12:30 PM Central Time

Digital Behavioral Therapy Improves Outcome in Patients With Axial Spondyloarthritis And Persistent Pain: Results From a Randomized Controlled Trial
Abstract Poster Presenter: Uta Kiltz, MD – Rheumazentrum Ruhrgebiet
10:30 AM - 12:30 PM Central Time

Effect of Guselkumab and IL-17 Inhibitors on Work Productivity and Activity Impairment in Psoriatic Arthritis: 6-Month Results of the PsABIOnd Observational Study
Abstract Poster Presenter: Stefan Siebert, MD – University of Glasgow
10:30 AM - 12:30 PM Central Time

Effective Prevention of Psoriatic Arthritis with Secukinumab: A 5-Year Observation from the SERENA Study
Abstract Poster Presenter: Uta Kiltz, MD – Rheumazentrum Ruhrgebiet
10:30 AM - 12:30 PM Central Time

Efficacy and Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis by Cigarette Smoking Status: A Post Hoc Analysis of a Randomized, Double-blind, Phase 2/3 Study
Abstract Poster Presenter: Hongbin Li, MD – Affiliated Hospital of Inner Mongolia Medical University
10:30 AM - 12:30 PM Central Time

Five-Year Results of Secukinumab on Minimal Disease Activity (MDA) Components and the Impact of Biologic Treatment Status on Effectiveness and Safety in Patients With Psoriatic Arthritis: Real-World Data From the SERENA Study
Abstract Poster Presenter: Uta Kiltz, MD – Rheumazentrum Ruhrgebiet
10:30 AM - 12:30 PM Central Time

Fungal Infections, Including Candida, in Patients With Active Psoriatic Arthritis (PsA) Treated With Secukinumab: A Pooled Analysis of 9 Phase 3 Trials
Abstract Poster Presenter: Shikha Singla, MD – MCW
10:30 AM - 12:30 PM Central Time

Impact of Bimekizumab on Spinal MRI Inflammation and Structural Lesions in Patients with Radiographic Axial Spondyloarthritis: 2-Year CANDEN Scoring Results from a Phase 3 Study and Its Open-Label Extension
Abstract Poster Presenter: Walter P P. Maksymowych, MD, FRCPC, MRCP, FACP – University of Alberta
10:30 AM - 12:30 PM Central Time

Impact of Treatment With Upadacitinib on Non-Nociceptive Pain and Its Relevance for the Presence of Residual Symptoms in Axial Spondyloarthritis: Results from a Multicountry Observational Study
Abstract Poster Presenter: Denis Poddubnyy, MD, PhD, MSc – University of Toronto
10:30 AM - 12:30 PM Central Time

Incidence of Major Adverse Cardiovascular Events (MACE) in Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis Patients With and Without Cardiovascular Risk Factors Treated With Secukinumab: Five-Year Safety Data from the Real-World SERENA Study
Abstract Poster Presenter: Uta Kiltz, MD – Rheumazentrum Ruhrgebiet
10:30 AM - 12:30 PM Central Time

Influence of Sex on the Therapeutic Persistence of Guselkumab in Psoriatic Disease: a Retrospective National Cohort Study
Abstract Poster Presenter: Laure Gossec, MD;PhD – Sorbonne Universite and Pitie-Salpetriere Hospital
10:30 AM - 12:30 PM Central Time

Long-term impact of secukinumab on the prevention of psoriatic arthritis in patients with psoriasis: a 5-year pooled analysis of the ERASURE, FIXTURE and SCULPTURE studies
Abstract Poster Presenter: Laura Coates, MD, PhD – University of Oxford
10:30 AM - 12:30 PM Central Time

Long-Term Safety and Efficacy of Upadacitinib in Patients With Psoriatic Arthritis: 5-Year Results From the Phase 3 SELECT-PsA 1 Study
Abstract Poster Presenter: Iain McInnes, PhD, FRCP – University of Glasgow
10:30 AM - 12:30 PM Central Time

Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
10:30 AM - 12:30 PM Central Time

Long-Term Safety of Tildrakizumab Through Week 208 in Patients With Psoriatic Arthritis: Results From the Phase 2b Open-Label Extension Study
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
10:30 AM - 12:30 PM Central Time

Modulation of Soluble Biomarkers of Cartilage and Bone Turnover and Inflammation by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent TYK2 Inhibitor, is Associated with Clinical Response in Patients with Active Psoriatic Arthritis
Abstract Poster Presenter: Iain McInnes, PhD, FRCP – University of Glasgow
10:30 AM - 12:30 PM Central Time

Patient Characteristics, and Physician-Reported Treatment Effectiveness and Treatment Satisfaction with Bimekizumab for Axial Spondyloarthritis in the United States: Interim Analysis from a Real-World Study
Abstract Poster Presenter: Jessica Walsh, MD, MBA – Salt Lake City Veterans Affairs Health and University of Utah Health
10:30 AM - 12:30 PM Central Time

Persistence of Second-line Treatment in Anti-TNF-experienced Axial Spondyloarthritis Patients: Comparing Cycling Anti–TNF vs Switching to a Different Mechanism of Action
Abstract Poster Presenter: José Miguel Senabre, MD, PhD – Hospital Marina Baixa
10:30 AM - 12:30 PM Central Time

Real-world comparative effectiveness of tofacitinib, tumor necrosis factor inhibitors, and interleukin-17 inhibitors among patients with axial spondyloarthritis
Abstract Poster Presenter: Jeffrey Curtis, MD, MS, MPH – University of Alabama at Birmingham
10:30 AM - 12:30 PM Central Time

Real-World Comparative Effectiveness of Upadacitinib in Psoriatic Arthritis: Evaluation of Switching to Upadacitinib Versus Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors After First-Line Tumor Necrosis Factor Inhibitors
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
10:30 AM - 12:30 PM Central Time

Real-world Patient Trajectories in Psoriasis and Psoriatic Arthritis: a Retrospective Study
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
10:30 AM - 12:30 PM Central Time

Safety of Prescription NSAIDs in Adults with IBD: Data from a Large Administrative Claims Cohort
Abstract Poster Presenter: Adam Mayer, MD – Hackensack University Medical Center
10:30 AM - 12:30 PM Central Time

Similar Efficacy of Bimekizumab in Two Clinical Endotypes of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies and Their Open-Label Extension
Abstract Poster Presenter: Félicie Costantino, MD, PhD – AP-HP
10:30 AM - 12:30 PM Central Time

Sonelokimab in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs: Phase 2 ARGO Analysis and Phase 3 IZAR-1 Study Design
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
10:30 AM - 12:30 PM Central Time

Sustainability of Clinical Response Through 2 Years Among Upadacitinib-Treated Patients With Axial Spondyloarthritis: Data From the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
Abstract Poster Presenter: Victoria Navarro-Compán, MD – La Paz University Hospital
10:30 AM - 12:30 PM Central Time

The Novel Digital Therapeutic Axia Improves Disease Activity, Functionality, and Quality of Life in Axial Spondyloarthritis Patients: Results from a Randomized Controlled Trial (Bechterew-App Trial)
Abstract Poster Presenter: Marc Schmalzing, MD – University Hospital Wuerzburg